A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2017
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Hydrocortisone; J 591-radiolabelled; Ketoconazole
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 11 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 11 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.